171 related articles for article (PubMed ID: 33619196)
21. Diagnostic accuracy of faecal calprotectin in a symptom-based algorithm for early diagnosis of inflammatory bowel disease adjusting for differential verification bias using a Bayesian approach.
Viola A; Fontana A; Belvedere A; Scoglio R; Costantino G; Sitibondo A; Muscianisi M; Inferrera S; Bruno LM; Alibrandi A; Trifirò G; Fries W
Scand J Gastroenterol; 2020 Oct; 55(10):1176-1184. PubMed ID: 32838582
[TBL] [Abstract][Full Text] [Related]
22. Faecal calprotectin delivers on convenience, cost reduction and clinical decision-making in inflammatory bowel disease: a real-world cohort study.
Motaganahalli S; Beswick L; Con D; van Langenberg DR
Intern Med J; 2019 Jan; 49(1):94-100. PubMed ID: 29962008
[TBL] [Abstract][Full Text] [Related]
23. Faecal calprotectin testing for identifying patients with organic gastrointestinal disease: systematic review and meta-analysis.
An YK; Prince D; Gardiner F; Neeman T; Linedale EC; Andrews JM; Connor S; Begun J
Med J Aust; 2019 Nov; 211(10):461-467. PubMed ID: 31680263
[TBL] [Abstract][Full Text] [Related]
24. Noninvasive testing in the management of children with suspected inflammatory bowel disease.
Dilillo D; Zuccotti GV; Galli E; Meneghin F; Dell'Era A; Penagini F; Colella G; Lewindon P; Carmagnola S; Farina E; Ardizzone S; Maconi G
Scand J Gastroenterol; 2019 May; 54(5):586-591. PubMed ID: 31032665
[No Abstract] [Full Text] [Related]
25. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease.
Henderson P; Casey A; Lawrence SJ; Kennedy NA; Kingstone K; Rogers P; Gillett PM; Wilson DC
Am J Gastroenterol; 2012 Jun; 107(6):941-9. PubMed ID: 22370604
[TBL] [Abstract][Full Text] [Related]
26. Utility of Fecal Calprotectin in Evaluation of Chronic Gastrointestinal Symptoms in Primary Care.
Ramraj R; Garcia A; Mosen D; Waiwaiole L; Smith N
Clin Pediatr (Phila); 2018 Aug; 57(9):1058-1063. PubMed ID: 29192504
[TBL] [Abstract][Full Text] [Related]
27. Faecal calprotectin: current usage and perceived beneficial effects of third-party funding on rates of colonoscopy by Australian gastroenterologists.
Elnawsra O; Fok I; Sparrow M; Gibson P; Andrews J; Connor S
Intern Med J; 2016 May; 46(5):590-5. PubMed ID: 26946938
[TBL] [Abstract][Full Text] [Related]
28. Negative Effects on Psychological Health and Quality of Life of Genuine Irritable Bowel Syndrome-type Symptoms in Patients With Inflammatory Bowel Disease.
Gracie DJ; Williams CJ; Sood R; Mumtaz S; Bholah MH; Hamlin PJ; Ford AC
Clin Gastroenterol Hepatol; 2017 Mar; 15(3):376-384.e5. PubMed ID: 27189912
[TBL] [Abstract][Full Text] [Related]
29. Fecal calprotectin is an effective diagnostic tool that differentiates inflammatory from functional intestinal disorders.
Caviglia GP; Pantaleoni S; Touscoz GA; Adriani A; Rosso C; Smedile A; Pellicano R; Astegiano M; Bresso F
Scand J Gastroenterol; 2014 Dec; 49(12):1419-24. PubMed ID: 25369978
[TBL] [Abstract][Full Text] [Related]
30. The diagnostic accuracy of fecal calprotectin during the investigation of suspected pediatric inflammatory bowel disease: a systematic review and meta-analysis.
Henderson P; Anderson NH; Wilson DC
Am J Gastroenterol; 2014 May; 109(5):637-45. PubMed ID: 23670113
[TBL] [Abstract][Full Text] [Related]
31. Effect of faecal calprotectin assay variability on the management of inflammatory bowel disease and potential role of faecal S100A12.
Whitehead SJ; Ford C; Gama RM; Ali A; McKaig B; Waldron JL; Steed H; Brookes MJ
J Clin Pathol; 2017 Dec; 70(12):1049-1056. PubMed ID: 28735301
[TBL] [Abstract][Full Text] [Related]
32. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation.
Fu Y; Wang L; Xie C; Zou K; Tu L; Yan W; Hou X
Sci Rep; 2017 Jun; 7(1):2669. PubMed ID: 28572616
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Accuracy of Fecal Calprotectin for Pediatric Inflammatory Bowel Disease in Primary Care: A Prospective Cohort Study.
Holtman GA; Lisman-van Leeuwen Y; Kollen BJ; Norbruis OF; Escher JC; Kindermann A; de Rijke YB; van Rheenen PF; Berger MY
Ann Fam Med; 2016 Sep; 14(5):437-45. PubMed ID: 27621160
[TBL] [Abstract][Full Text] [Related]
34. Automated Fecal Biomarker Profiling - a Convenient Procedure to Support Diagnosis for Patients with Inflammatory Bowel Diseases.
Kraemer A; Bulgakova T; Schukina O; Kharitidis A; Kharitonov A; Korostovtseva E; Hammar F; Bang H; Lapin S
Clin Lab; 2020 Jul; 66(7):. PubMed ID: 32658433
[TBL] [Abstract][Full Text] [Related]
35. Faecal calprotectin as a novel biomarker for differentiating between inflammatory bowel disease and irritable bowel syndrome.
Chang MH; Chou JW; Chen SM; Tsai MC; Sun YS; Lin CC; Lin CP
Mol Med Rep; 2014 Jul; 10(1):522-6. PubMed ID: 24788223
[TBL] [Abstract][Full Text] [Related]
36. Evaluation of point-of-care test calprotectin and lactoferrin for inflammatory bowel disease among children with chronic gastrointestinal symptoms.
Holtman GA; Lisman-van Leeuwen Y; van Rheenen PF; Kollen BJ; Escher JC; Kindermann A; de Rijke YB; Berger MY
Fam Pract; 2017 Aug; 34(4):400-406. PubMed ID: 27535331
[TBL] [Abstract][Full Text] [Related]
37. A comparison of diagnostic performance between two quantitative rapid fecal calprotectin assays in detecting active inflammatory bowel disease.
Lee JM; Jang JH; Ryu JH; Yoo J; Lee BI; Kim SJ; Oh EJ
PLoS One; 2021; 16(8):e0255974. PubMed ID: 34383847
[TBL] [Abstract][Full Text] [Related]
38. VAlidation of an 8-item-questionnaire predictive for a positive caLprotectin tEst and Real-life implemenTation in primary care to reduce diagnostic delay in inflammatory bowel disease (ALERT): protocol for a prospective diagnostic study.
Hasler S; Zahnd N; Müller S; Vavricka S; Rogler G; Tandjung R; Rosemann T
BMJ Open; 2015 Mar; 5(3):e007306. PubMed ID: 25757949
[TBL] [Abstract][Full Text] [Related]
39. Comparing outcomes from tailored meta-analysis with outcomes from a setting specific test accuracy study using routine data of faecal calprotectin testing for inflammatory bowel disease.
Freeman K; Willis BH; Ryan R; Taylor-Phillips S; Clarke A
BMC Med Res Methodol; 2022 Jul; 22(1):192. PubMed ID: 35820893
[TBL] [Abstract][Full Text] [Related]
40. FOCUS: Future of fecal calprotectin utility study in inflammatory bowel disease.
Rosenfeld G; Greenup AJ; Round A; Takach O; Halparin L; Saadeddin A; Ho JK; Lee T; Enns R; Bressler B
World J Gastroenterol; 2016 Sep; 22(36):8211-8. PubMed ID: 27688663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
